Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 2/20 | 0.49 |
| ▸ | DGKA | P23743 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | CES2 | O00748 | 3/20 | 0.45 |
| ▸ | CES1 | P23141 | 3/20 | 0.45 |
| ▸ | TSHR | P16473 | 5/20 | 0.44 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.43 |
| ▸ | PPARG | P37231 | 6/20 | 0.43 |
| ▸ | PPARD | Q03181 | 6/20 | 0.43 |
| ▸ | PPARA | Q07869 | 6/20 | 0.43 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | TLR2 | O60603 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | FABP4 | P15090 | 2/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.43 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.43 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ESR1 | P03372 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27143051 | 1.00 | FAAH (0.49) | FAAHDGKANPSR1CES2CES1 | |
| SCHEMBL31059241 | 1.00 | FAAH (0.49) | FAAHDGKANPSR1CES2CES1 | |
| SCHEMBL30914723 | 1.00 | FAAH (0.49) | FAAHDGKANPSR1CES2CES1 | |
| SCHEMBL30914724 | 1.00 | FAAH (0.49) | FAAHDGKANPSR1CES2CES1 | |
| SCHEMBL31403754 | 1.00 | FAAH (0.49) | FAAHDGKANPSR1CES2CES1 | |
| SCHEMBL26480658 | 1.00 | FAAH (0.49) | FAAHDGKANPSR1CES2CES1 | |
| SCHEMBL16012388 | 1.00 | FAAH (0.49) | FAAHDGKANPSR1CES2CES1 | |
| SCHEMBL31059245 | 1.00 | FAAH (0.49) | FAAHDGKANPSR1CES2CES1 | |
| SCHEMBL21827069 | 0.98 | NPSR1 (0.48) | FAAHDGKANPSR1CES2CES1 | |
| SCHEMBL27153983 | 0.93 | FAAH (0.44) | FAAHDGKATSHRGPR84PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250214925-A1 | CATIONIC LIPID, LIPOSOME, LIPID NANOPARTICLE, AND USE | CARCELL BIOPHARMA LTD. (CN) | 2025-07-03 | — | — | US | disclosed |
| EP-4488259-A1 | CATIONIC LIPID, LIPOSOME, LIPID NANOPARTICLE, AND USE | Carcell Biopharma Ltd. (CN) | 2025-01-08 | — | — | EP | disclosed |
| CN-118974004-A | Cationic lipids, liposomes, lipid nanoparticles and uses | 科镁信（上海）生物医药科技有限公司 | 2024-11-15 | — | — | CN | disclosed |
| WO-2023186171-A1 | CATIONIC LIPID, LIPOSOME, LIPID NANOPARTICLE, AND USE | 科镁信（上海）生物医药科技有限公司 | 2023-10-05 | — | — | WO | disclosed |
| WO-2023186167-A1 | CATIONIC LIPID, LIPOSOME, LIPID NANOPARTICLE, AND USE | 科镁信（上海）生物医药科技有限公司 | 2023-10-05 | — | — | WO | disclosed |
| US-20140248317-A1 | TREHALOSE COMPOUND, METHOD FOR PRODUCING SAME, AND PHARMACEUTICAL PRODUCT CONTAINING THE COMPOUND | GLYTECH, INC. (JP) | 2014-09-04 | — | — | US | disclosed |
| US-20140248317-A1 | TREHALOSE COMPOUND, METHOD FOR PRODUCING SAME, AND PHARMACEUTICAL PRODUCT CONTAINING THE COMPOUND | GLYTECH, INC. (JP) | 2014-09-04 | — | — | US | disclosed |
| US-8741871-B2 | Trehalose compound, method for producing same, and pharmaceutical product containing the compound | GLYTECH, INC. (JP) | 2014-06-03 | — | — | US | disclosed |
| CN-102203110-A | Trehalose compound, method for producing same, and pharmaceutical product containing the compound | OTSUKA CHEMICAL CO LTD | 2011-09-28 | — | — | CN | disclosed |
| US-20110218171-A1 | TREHALOSE COMPOUND, METHOD FOR PRODUCING SAME, AND PHARMACEUTICAL PRODUCT CONTAINING THE COMPOUND | OTSUKA CHEMICAL CO., LTD. (JP) | 2011-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110218171-A1 | TREHALOSE COMPOUND, METHOD FOR PRODUCING SAME, AND PHARMACEUTICAL PRODUCT CONTAINING THE COMPOUND | TREH, MAN2B1, NFATC1 | FAAH 3687/4885DGKA 2343/4885NPSR1 1612/4885 |
| US-20140248317-A1 | TREHALOSE COMPOUND, METHOD FOR PRODUCING SAME, AND PHARMACEUTICAL PRODUCT CONTAINING THE COMPOUND | TREH, MAN2B1, NFATC1 | FAAH 3687/4885DGKA 2343/4885NPSR1 1612/4885 |
| US-20250214925-A1 | CATIONIC LIPID, LIPOSOME, LIPID NANOPARTICLE, AND USE | LIPA, LIPC, ABCB4 | FAAH 279/4885DGKA 546/4885NPSR1 2894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.